Lifevantage Target of Unusually Large Options Trading (NASDAQ:LFVN)

Lifevantage Corporation (NASDAQ:LFVN) saw some unusual options trading activity on Wednesday. Stock investors bought 2,482 call options on the stock. This represents an increase of 747% compared to the average daily volume of 293 call options.

Insider Activity at Lifevantage

In other Lifevantage news, Director Judd Dayton acquired 10,500 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was acquired at an average cost of $4.53 per share, for a total transaction of $47,565.00. Following the transaction, the director directly owned 80,359 shares in the company, valued at $364,026.27. This represents a 15.03% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 21.95% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE increased its stake in shares of Lifevantage by 24.3% in the 1st quarter. Bank of America Corp DE now owns 23,445 shares of the company’s stock valued at $101,000 after acquiring an additional 4,586 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Lifevantage by 11.9% in the 1st quarter. Bank of New York Mellon Corp now owns 33,547 shares of the company’s stock worth $145,000 after acquiring an additional 3,571 shares during the last quarter. Hsbc Holdings PLC purchased a new stake in shares of Lifevantage in the first quarter worth approximately $51,000. DGS Capital Management LLC bought a new position in shares of Lifevantage in the first quarter valued at approximately $44,000. Finally, Aristides Capital LLC bought a new position in shares of Lifevantage in the fourth quarter valued at approximately $76,000. Institutional investors own 35.32% of the company’s stock.

Lifevantage Price Performance

Shares of NASDAQ LFVN opened at $7.67 on Friday. The company has a 50 day simple moving average of $4.96 and a 200 day simple moving average of $5.54. Lifevantage has a 1 year low of $3.90 and a 1 year high of $15.00. The firm has a market cap of $96.80 million, a PE ratio of 17.04 and a beta of 0.52.

Lifevantage (NASDAQ:LFVN) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.16 by ($0.04). The business had revenue of $43.72 million during the quarter, compared to analyst estimates of $47.77 million. Lifevantage had a net margin of 2.94% and a return on equity of 23.89%. As a group, research analysts anticipate that Lifevantage will post 0.6 earnings per share for the current fiscal year.

Lifevantage Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, June 15th. Investors of record on Monday, June 1st will be issued a $0.05 dividend. The ex-dividend date is Monday, June 1st. This is a boost from Lifevantage’s previous quarterly dividend of $0.05. This represents a $0.20 annualized dividend and a yield of 2.6%. Lifevantage’s dividend payout ratio (DPR) is currently 40.00%.

Analyst Upgrades and Downgrades

LFVN has been the subject of a number of research reports. Lake Street Capital cut shares of Lifevantage from a “buy” rating to a “hold” rating and set a $5.00 target price for the company. in a report on Thursday, May 7th. Loop Capital set a $5.00 price objective on shares of Lifevantage in a research report on Thursday, February 5th. Finally, Weiss Ratings raised shares of Lifevantage from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday. Two investment analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $5.00.

Lifevantage Company Profile

LifeVantage Corporation is a publicly traded company that develops, markets and distributes nutritional supplements, skincare products and weight-management solutions through a direct-selling business model. The company’s flagship offering, Protandim®, is formulated to activate the Nrf2 pathway, which is associated with cellular defense processes. LifeVantage also markets the PhysIQ® line for metabolism and body composition support and the TrueScience® skincare regimen, targeting a range of health and wellness needs.

Founded in 1999 and headquartered in Sandy, Utah, LifeVantage combines research in nutrigenomics with a network of independent distributors to bring its products to market.